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Abstract
Nasopharyngeal carcinoma is a unique disease entity among head and neck 
cancers due to its epidemiology and clinical behavior. Non-keratinizing or undif-
ferentiated carcinoma is the most common histological type in endemic areas. 
Radiotherapy is the treatment for early-stage disease. With the widespread use of 
IMRT, loco-regional control has improved significantly in locally advanced diseases. 
But distant metastasis continues to be the most common pattern of failure. To 
address this issue, chemotherapy has been incorporated into radiotherapy in various 
settings; as concurrent, induction, and adjuvant. The initial trials of concurrent 
chemotherapy incorporated adjuvant chemotherapy also and the magnitude of ben-
efit contributed by each treatment was not clear. Later trials proved that adjuvant 
chemotherapy was not beneficial. Induction chemotherapy when added to concur-
rent chemoradiation resulted in improvement in Failure Free Survival, Overall 
Survival, and Distant Metastasis Free Survival. Thus, induction chemotherapy 
followed by concurrent chemoradiation became the standard of care for locally 
advanced disease (stage III and IVA). The role of chemotherapy in stage II disease is 
still evolving. Metastatic nasopharyngeal carcinoma is treated by platinum doublet 
chemotherapy, Cisplatin-gemcitabine is the standard regimen.
Keywords: Nasopharyngeal carcinoma, locally advanced, metastatic, concurrent 
chemotherapy, induction chemotherapy, adjuvant chemotherapy
1. Introduction
Nasopharyngeal carcinoma (NPC) is unique from other head and neck cancers 
due to its difference in epidemiology, etiology and propensity for distant metastasis. 
It is endemic in Southern China, South East Asia, North Africa, and Artic region. 
Non-keratinizing or undifferentiated carcinoma is the most common histological 
type in endemic areas. Radiotherapy is the backbone of treatment owing to the 
complex anatomical location and high radiosensitivity. Higher local control and 
survival are reported for early-stage disease with radiotherapy alone [1]. But around 
70% of patients present with locoregionally advanced disease and outcomes with 
radiotherapy alone are poor [2]. Many strategies have been tried to improve outcomes 
in locoregionally advanced NPC; the incorporation of chemotherapy and the use 
of modern radiotherapy techniques. IMRT when compared with two-dimensional 
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radiotherapy showed significantly better locoregional control and survival with 
a lower incidence of radiation- induced toxicities [3, 4]. IMRT is mainly aimed at 
reducing the toxicities in the early stages whereas it improves loco-regional control 
(LRC) in advanced stages. After the widespread use of IMRT, distant metastasis 
remains the predominant pattern of failure. Hence chemotherapy was added to radio-
therapy in various settings; as concurrent, induction, and adjuvant. Patients with 
metastatic disease are treated by palliative chemotherapy or palliative radiotherapy.
2. Evolution of chemoradiation in NPC
Stage I disease is treated by radical radiotherapy. Locally advanced disease 
(stage III and IVA) was treated by radiotherapy till the early ‘90s. Chemo-radiation 
was first studied in the landmark intergroup trial by Al Saraaf et al [5]. This trial 
compared chemoradiation followed by adjuvant chemotherapy versus radiotherapy 
(RT) alone in stage III and IV NPC (N = 147). The radiotherapy dose was 70Gy, 
delivered by conformal technique. There was a significant improvement in PFS and 
OS with the addition of chemotherapy. The 3-year PFS rate was 69% versus 24% 
(P < .001) and the 3-year OS was 78% versus 47% (P = .005) in the chemoradiation 
and radiotherapy arms respectively. But this trial was conducted in a non-endemic 
area and 22% of patients had keratinizing SCC. Hence the results could not be 
extrapolated to endemic areas.
Four randomized trials were conducted in a similar fashion in the endemic 
population, one each from Singapore and China and two from Hongkong. Wee  
et al randomized patients (N = 221) with stage T3-4NxM0 or TxN2-3 M0 NPC with 
WHO type II or III histology to radiotherapy alone or chemoradiotherapy followed 
by adjuvant chemotherapy [6]. Patients on chemoradiotherapy received concur-
rent cisplatin (25 mg/m2 on days 1 to 4) on weeks 1, 4, and 7 of RT and adjuvant 
cisplatin (20 mg/m2 on days 1 to 4) and fluorouracil (1,000 mg/m2 on days 1 to 4) 
every 4 weeks (weeks 11, 15, and 19) for three cycles after completion of RT. RT 
dose was 70Gy in 7 weeks by conventional technique. The 3-year survival rate was 
65% and 80% for RT alone and CCRT, respectively (HR 0.51 (95% CI, 0.31 to 0.81; 
P = .0061). There was a 17% decrease in cumulative incidence of distant metastasis 
in the chemotherapy arm (p = 0029).
Two parallel RCTs from Hongkong namely NPC 9901 and NPC 9902 were 
done for advanced regional disease and advanced local disease respectively in the 
endemic population [7, 8]. In NPC 9901, patients with nonkeratinizing/undifferen-
tiated NPC staged T1–4N2-3 M0 were randomized to chemo-RT followed by adju-
vant chemotherapy or RT alone (N = 348). There was a significant improvement 
in LRC and failure free survival (FFS) but at the expense of significantly higher 
rates of acute and late toxicities. The update also showed significant improvement 
in 5 year FFS (67% vs 55%, P = .014) and PFS (62% vs 53%, P = .035) in favor of 
chemotherapy [9]. There was an increase in acute toxicities (CRT vs RT: 83% vs 
53%; P < .001), but late toxicities were not different. OS did not show any benefit, 
probably due to the increased rates of noncancer death in the chemotherapy arm. 
NPC 9902 included Stage T3-4N0-1M0, nonkeratinizing or undifferentiated 
carcinoma of the nasopharynx (N = 189). There were 4 arms; RT with conventional 
fractionation alone, RT with accelerated fractionation alone, RT with conventional 
fractionation + concurrent /adjuvant chemotherapy (CF + C), and RT with acceler-
ated fractionation + concurrent/ adjuvant chemotherapy (AF- + C). There was a 
significant improvement in FFS in the AF + C compared to the CF arm (94% vs. 
70% at 3 years, p = 0.008), but the difference was not significant between the AF 
arm and the CF + C. There was no significant difference in OS between the 4 arms. 
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Acute toxicities were significantly more in both the chemo-RT arms. The late toxic-
ity was more in the AF + C arm compared to the CF arm(p = 0.05).
Another prospective trial with a similar design was conducted in the endemic 
population of China by Chen et al [10]. RT dose was 70Gy in 7 weeks by conven-
tional technique. The chemotherapy arm received concurrent cisplatin (40 mg/m2 
on Day 1) weekly during RT, followed by cisplatin (80 mg/m2 on Day 1) and fluoro-
uracil (800 mg/m2 on Days 1–5) every 4 weeks (Weeks 5, 9, and 13) for three cycles 
after completion of RT. The 2 year overall survival rate (89.8% vs. 79.7%, p = 0.003), 
failure-free survival rate (84.6% vs. 72.5%, p = 0.001), distant failure-free survival 
rate (86.5% vs. 78.7%, p = 0.024), and locoregional failure-free survival rate (98.0% 
vs. 91.9%, p = 0.007) was better in the chemotherapy arm. But acute toxicities were 
more in the chemotherapy arm (62.6% vs. 32%, p = 0.000).
Different trials used different concurrent cisplatin schedules. A randomized 
phase 3 trial was conducted by Liang et al to identify the ideal concurrent regimen. 
Weekly cisplatin 40 mg/m2 was shown to have efficacy similar to 3 weekly cisplatin 
100 mg/m2 but at the expense of increased hematological toxicities [11].
The chemoradiation trials showed improvement in failure-free survival and 
distant metastasis-free survival with the addition of chemotherapy at the expense 
of increased acute toxicities. But overall survival benefit was not consistent among 
trials. A meta-analysis of 7 randomized trials done in endemic population by Zhang 
et al showed significantly better 5 years OS in favor of the CCRT treatment groups 
with a relative risk (RR) of 0.74 [0.62–0.89]. Locoregional recurrence (RR of 
0.67,95% CI, 0.49 to 0.91) and distant metastasis (RR of 0.71;95% CI, 0.58 to 0.88) 
was significantly lower in the chemo-RT arm [12].
A meta-analysis with ten RCTs was done by Langendijk et al (4 neoadjuvant 
trials, 3 concurrent +/−adjuvant trials, and 2 adjuvant trials) to identify the addi-
tional benefit of chemotherapy when added to radiation [13]. There was an absolute 
survival benefit of 4% at 5 years with chemotherapy. Among the three chemother-
apy timings, concomitant chemotherapy was associated with an absolute survival 
benefit of 20% at 5 years (HR of 0.48 (95% CI, 0.32 to 0.72). There was a significant 
reduction in locoregional recurrences with the addition of chemotherapy. The RR 
for locoregional recurrence was 0.47 (p < 0.0001) with concomitant chemotherapy 
and 0.74 (p = 0.005) with induction chemotherapy. But there was no benefit with 
adjuvant chemotherapy for locoregional control. The addition of chemotherapy 
demonstrated significant benefit in reducing distant metastasis also(p < 0.001).
The MAC NPC collaborative group meta-analysis included trials 8 trials that 
used chemotherapy in induction, concurrent or adjuvant setting [14]. There was an 
absolute survival benefit of 6% at 5 years with the addition of chemotherapy to RT 
which corresponds to an 18% reduction in the HR of death (HR 0.82; p = 0.006). 
The concomitant schedule showed more benefit (HR = 0.60) than induction 
(HR = 0.99) and adjuvant (HR = 0.97) regimens. There was an absolute EFS benefit 
of 10% at 5 years with the addition of chemotherapy. Chemotherapy decreased the 
risk of locoregional failure (p 0.003; HR, 0.76) and distant failure (p = 0.001; HR, 
0.72) irrespective of the timing of chemotherapy. Chemotherapy was more efficient 
against WHO type 1 disease than against WHO type 2 or 3 diseases (p = 0.003 
for OS and p = 0.0001 for EFS). The survival outcomes were favoring the chemo-
therapy arms even after excluding WHO type 1 patients (p = 0.03).
The updated MAC NPC meta-analysis included 19 trials and with a median 
follow-up of 7.7 years [15]. There was an absolute survival benefit of 6.3% at 5 years 
by the addition of chemotherapy to radiotherapy. The addition of chemotherapy 
resulted in significant improvement in PFS, LRC, distant control, and cancer 
mortality. The outcome was analyzed separately for concurrent chemotherapy with 
or without adjuvant chemotherapy. The benefit of chemotherapy was dependent 
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on the timing of chemotherapy. HR was 0·65 (0·56–0·76) for concomitant plus 
adjuvant chemotherapy, and 0·80 (0·70–0·93) for concomitant with out adjuvant 
chemotherapy. There was no significant benefit with induction chemotherapy alone 
or adjuvant chemotherapy alone.
A meta-analysis of 28 RCTs on the association of chemoradiotherapy regimens 
and survival done by Zhang et al showed that concurrent chemoradiotherapy 
(CCRT) was significantly associated with improved OS, PFS, DMFS, and LRFS 
compared with radiotherapy. The addition of induction chemotherapy resulted 
in improvement in OS ([HR 0.84; 95%CI 0.74–0.95), PFS (HR 0.73; 95% CI, 
0.64–0.84), DMFS (HR, 0.67; 95% CI, 0.59–0.78), and LRFS (HR, 0.74; 95% 
CI, 0.64–0.85). The addition of adjuvant chemotherapy was not associated with 
survival benefits [16].
3. Role of adjuvant chemotherapy after concurrent chemoradiation
The above-mentioned five chemoradiation trials used adjuvant chemotherapy also. 
Hence the benefit of adjuvant chemotherapy when added to chemoradiation is not 
clear. Moreover, with the advancements in radiation techniques, the local control has 
increased significantly and distant metastasis remains the common mode of failure. 
This prompted investigators to test the value of adjuvant chemotherapy when added to 
chemoradiation. Chen et al randomized stage III and IV nonmetastatic non-keratinizing 
NPC patients to concurrent chemoradiotherapy plus adjuvant chemotherapy ver-
sus concurrent chemoradiotherapy alone. Cisplatin 40 mg/m2 weekly was used as 
the concurrent regimen. Adjuvant chemotherapy consisted of 3 cycles of cisplatin 
80 mg/m on day 1 and 5FU 800 mg/m2 per day on days 1–5. After a median follow-up of 
37·8 months, the 2 year FFS was 86% in the adjuvant chemotherapy group compared to 
84% in the CCRT group(p = .13). There was no significant difference in Overall survival, 
Distant failure-free survival, and loco-regional failure-free survival [17]. The update 
also showed similar results [18]. The outcomes in the two arms were similar irrespective 
of the radiotherapy technique (2D vs 3Dvs IMRT). All three cycles of adjuvant chemo-
therapy were completed by only 63% of patients in the adjuvant arm.
Adjuvant chemotherapy after concurrent chemoradiation is associated with 
significant toxicities and poor compliance without any survival advantage. There 
is no evidence to recommend routine use of adjuvant chemotherapy in locally 
advanced NPC.
4. Adjuvant chemotherapy-risk adjusted treatment
EBV is related to NPC in endemic areas. EBV DNA load has been correlated 
with the prognosis of NPC in many studies [19, 20]. Hong Kong 0502 trial included 
patients with detectable plasma EBV DNA after curative radiotherapy. Patients were 
randomized to adjuvant chemotherapy with cisplatin-gemcitabine or observation 
[20]. After a median follow-up of 6.6 years, there was no significant difference in 
the 5-year relapse-free survival (RFS) rate between the two arms (49.3% versus 
54.7%; HR 1.09, P = 0.75).
5. Induction chemotherapy in NPC
Concurrent chemo-RT with advanced radiotherapy techniques have increased 
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Table 1. 
Phase 3 trials of induction chemotherapy in locally advanced nasopharyngeal carcinoma.
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to be a major problem and hence adjuvant chemotherapy was tried. But it failed to 
show benefit and the compliance to chemotherapy after chemoradiation was poor. 
Induction chemotherapy was tried to decrease the rates of distant metastasis, to 
increase survival, and to reduce radiotherapy toxicities by decreasing treatment 
volumes.
Six randomized trials on induction chemotherapy have been published; three 
from China, one each from Europe, Taiwan, and Singapore. These trials used 
different induction regimens, radiotherapy techniques, and dosage schedules. The 
three Chinese trials showed improvement in DFS, OS, and DMFS with the addition 
of induction chemotherapy [21–25]. But GORTEC, Taiwan, and Singapore trials did 
not show any advantage in terms of DMFS or OS [26–28]. All these trials reported 
significantly higher rates of acute toxicities with induction chemotherapy. Jin et al 
tested TPF against PF as induction therapy in locally advanced NPC and reported 
similar outcomes with better tolerance and compliance in the PF arm [29]. The 
details of induction chemotherapy trials are given in Table 1.
Three meta-analyses of induction chemotherapy have been published. Tan et al 
included 6 RCTs and five observational studies with 2802 patients. Induction che-
motherapy was associated with significantly improved PFS (HR 0.69, P = 0.0003) 
and OS (HR 0.77, P = 0.03,) at the expense of increased toxicities. There was a 
statistically significant 37% reduction in the hazard for the development of dis-
tant metastases (HR 0.63, P = 0.001) in favor of induction chemotherapy [30]. 
Individual patient data pooled analysis of 4 randomized trials from endemic areas 
by Chen et al reported an absolute benefit of 9.3% in 5 year PFS with the addition 
of induction chemotherapy to CCRT (P = 0.0009). Induction chemotherapy also 
improved OS (HR = 0.75; p = 0.04) and reduced distant failure (HR0.68; P = 0.008) 
[31]. Meta-analysis of 8 randomized trials with 2384 patients by Mane et al reported 
a significant benefit in OS (HR 0.68, P = 0.001) and PFS (HR 0.657, P < 0.001) with 
the addition of induction chemotherapy to CCRT, but acute toxicities were more 
with induction chemotherapy [32].
Induction chemotherapy before chemoradiation is associated with improvement 
in PFS, OS, and DMFS. TPF did not show any advantage over PF and the optimal 
induction regimens are cisplatin-infusion 5FU and cisplatin-gemcitabine.
6. Chemotherapy in stage II NPC
Radical radiotherapy is the treatment for stage I disease. Stage III and IVA are 
managed by induction chemotherapy followed by chemoradiation or chemora-
diotherapy with or without adjuvant chemotherapy. But the treatment of stage II 
disease is controversial. Stage II is a heterogeneous group with T2N0M0, T1N1M0, 
and T2N1M0disease. A phase 3 trial done by Chen et al in the conventional RT era 
randomized stage II patients into RT or CCRT [33]. Chemo-RT resulted in better 
5 year OS, PFS and Distant metastasis-free survival at the expense of increased 
acute toxicities. IMRT resulted in improvement in OS by reducing local and regional 
recurrence with decreased toxicities and better quality of life compared to 2D 
RT. The benefit of concurrent chemotherapy in the IMRT era is doubtful. Many 
comparative studies were done to study the effect of the addition of chemotherapy 
to IMRT. But most of the studies are retrospective in nature. A randomized phase 
2 trial by Huang et al showed no significant difference in OS, LFFS, RFFS, DFS, 
and DMFS after a median follow-up of 75 months. There was a detrimental effect 
on bone marrow function with chemo-RT [34]. Two retrospective studies from 
endemic areas showed no improvement in survival with the addition of chemother-
apy to IMRT [35, 36]. Propensity score matching analysis in intermediate-risk NPC 
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by Zhang et al showed no survival benefit (OS, FFS) by adding concurrent chemo-
therapy to IMRT [37]. Two meta-analyses of stage 2 trials have been published. Xu 
et al included 2D and IMRT studies [38]. CRT had significantly higher OS (HR 0.67, 
P = 0.04) and LRRFS (HR = 0.61, P = 0.0003) compared to RT alone, but there was 
no difference in DMFS. Acute toxicities were more in the chemo-RT arm. Subgroup 
analysis showed that IMRT alone achieved equivalent OS(P = 0.14), LRRFS(P-0.06) 
and DMFS(P = 0.89) compared to CRT. Liu et al published a meta-analysis of seven 
trials that compared IMRT alone with IMRT plus concurrent chemotherapy [39]. 
There was no benefit with the addition of chemotherapy to IMRT in terms of OS, 
PFS, DMFS, or LRRFS. Moreover CCRT was associated with increased rates of 
grade 3–4 leukopenia.
The benefit of adding chemotherapy to intensity-modulated radiotherapy in 
stage II disease is doubtful and is still under investigation.
7. Chemotherapy in metastatic NPC
Being a chemosensitive tumor, chemotherapy is the mainstay of treatment for 
metastatic NPC. Single-agent chemotherapy was used previously. Standard chemo-
therapy agents used now are platinum doublets with gemcitabine, 5FU, or paclitaxel 
[40, 41]. Higher response rates are associated with combination regimens than 
monotherapy. Cisplatin-5FU continuous infusion regimen resulted in a response 
rate of 55–65% [42]. Paclitaxel when added to carboplatin resulted in response rates 
as high as 75% [43]. A Randomized phase 3 trial from China compared Cisplatin 
gemcitabine (GP) with cisplatin 5FU(FP) in recurrent and metastatic NPC [44]. 
Gemcitabine plus cisplatin prolonged progression-free survival in patients with 
recurrent or metastatic NPC. The updated results showed an improvement in OS 
with Cisplatin -gemcitabine regimen (HR 0.723 (95% CI, 0.578 to 0.904; P = .004). 
The median OS was 22.1 months with GP versus 18.6 months with FP [45]. Triplet 
regimens tried in metastatic settings resulted in higher response rates and increased 
median OS, but with increased toxicities [46]. There is no head-on comparison 
with the standard doublets and triplet regimens are not recommended for first-line 
therapy.
These patients eventually progress on platinum-based chemotherapy due to 
the development of platinum resistance. The selection of second line treatment 
depends on the chemotherapy agent used in first line. The common second-line 
agents are 5-FU (including capecitabine), taxanes (paclitaxel, docetaxel), irinote-
can, vinorelbine, and gemcitabine [47–50] The response rates are inferior compared 
to the first-line agents.
8. Future directions
The role of adjuvant chemotherapy according to risk-adapted approach is evolv-
ing. Two trials of adjuvant chemotherapy according to post-treatment plasma EBV 
DNA measurements (NRG-HN001- NCT02135042 and NCT02363400) are under-
way [51, 52]. The benefit of concurrent chemotherapy in stage II NPC is not clear. 
NCT02610010, NCT02116231, and NCT02633202 are ongoing randomized phase2/3 
trials evaluating the same [53–55]. There is no proven role for targeted therapy or 
immunotherapy in locally advanced or metastatic NPC [56, 57]. A phase 3 trial 
(NCT02633176) comparing cisplatin, docetaxel plus cetuximab with cisplatin and 
docetaxel induction chemotherapy followed by concurrent chemoradiation in previ-
ously untreated metastatic NPC is underway [58]. PD-1 antibody Camrelizumab 
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is being compared with best supportive care after Chemoradiotherapy in 
Locoregionally Advanced NPC in a phase 3 trial [59]. Camrelizumab in combination 
with chemotherapy is tested against chemotherapy alone in recurrent and metastatic 
NPC in another randomized phase 3 trial [60].
9. Conclusion
Stage I NPC is treated by radical radiotherapy. Stage II disease is treated by IMRT 
alone or concurrent chemoradiation. Stage III and stage IVA disease are treated 
by induction chemotherapy followed by concurrent chemoradiation or concur-
rent chemoradiation +/−adjuvant radiotherapy. Metastatic NPC is usually treated 
by chemotherapy using platinum doublets, cisplatin-gemcitabine is the standard 
regimen.
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